Cipla launches India's first non-antibiotic drug for UTI
Women are more susceptible to UTI
image for illustrative purpose
New Delhi: Cipla on Friday announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent Urinary Tract Infections (UTIs), under the brand name HUENA.
UTIs are the second-most common reason for antibiotic use in India, with infection cases doubling over the last 30 years. "Women are more susceptible to UTI, which accounts for 15 per cent of overall antibiotic prescriptions," the company said.
According to the drug maker, Methenamine Hippurate offers an effective, non-antibiotic alternative for preventing UTIs by targeting bacteria in the bladder and urinary tract. Studies have shown it is as effective as long-term, low-dose antibiotic therapy for UTI prevention, with lower costs and no risk of antibiotic resistance. "The launch of HUENA reflects our strong commitment to antimicrobial stewardship and addressing the growing challenge of Anti-Microbial Resistance (AMR).
